The shame is the huge costs, and the marketing done by international private healthcare firms, that prey on MS patients. Using language, such as 'liberation therapy', has sucked in many who now suffer complications.
Last year, an Ontario man died after undergoing the treatment in Costa Rica. Mahir Mostic had surgery in June. Blood clots formed around the stent that was inserted in his neck; his friends said he couldn't find a doctor willing to treat him in Canada. The Niagara Falls man returned to Costa Rica in October, where he died soon after he was given medication to dissolve the clots, which may have triggered internal bleeding.
Dr. Paola Zamboni believed that the disease was caused by a narrowing of the arteries in the neck. We now know that this is a symptom of the disease, which also increases iron deposits in the brain.
A Google search brings up much information, as well as ads for apparent Mexican medical clinics that offer these 'treatments'. Surely we went through this for many other cancer treatments. Big promises for healing. The people that create these sites are paid by pharmaceuticals, individuals, owners of private retirement or LTC homes,
Canadians are traveling to Bulgaria, Poland, Mexico [They offer 'treatments' for many diseases. Ones we know cannot be cured.]. Some are remortgaging their homes to dig up the money.
There are web sites attacking those who are leading the research. One cannot even spell this researcher's name properly. (It's 'Luanne')
DR. LUANE METZ AND HER THREE YEAR GOALS | Facebook
30 Jul 2011 – C.C.S.V.I. - I.V.C.C. wrote a note titled DR. LUANE METZ AND HER THREE YEAR GOALS.
Researchers at the University of Calgary followed five patients who had undergone the so-called "liberation therapy," a treatment for MS developed by Italian researcher Paolo Zamboni. Zamboni believes the disease is caused by a narrowing of the vessels that drain blood from the brain, a condition called chronic cerebrospinal venous insufficiency, or CCSVI.
In their study, the Calgary researchers reported numerous complications in the five patients, including;
- Internal jugular vein stent thrombosis
- Cerebral sinovenous thrombosis
- Stent migration
- Cranial nerve injury
- Injury associated with venous catheterization
New studies and perspectives on CCSVI and MS are being published at an increasing rate. Click here to search for recent studies on PubMed, a service of the U.S. National Library of Medicine.
On June 11, 2010, the National MS Society (USA) and the MS Society of Canada announced the commitment of over $2.4 million to support 7 new research projects focusing on the role of CCSVI in the MS disease process. All research applications underwent a rigorous expedited review process by an international review panel that included experts drawn from all key relevant disciplines including radiology, vascular surgery and neurology. The U.S. National MS Society and the MS Society of Canada worked collaboratively to assemble the reviewers who considered scientific merit, responsiveness to the Request for Applications, experimental design, likelihood of producing definitive data, and the experience of the applicant teams in making their recommendations. This funding is only a part of the global Society effort underway to explore the CCSVI lead. The MS Society of Italy recently announced its intentions to support a 900,000 euro epidemiology study of CCSVI involving 1500 individuals with MS. This brings the international commitment of the MS Societies in pursuing the CCSVI lead to nearly $3.4 million.
Can J Neurol Sci. 2011 Sep;38(5):741-6.
Complications in MS Patients after CCSVI Procedures Abroad (Calgary, AB).
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
Background: The "chronic cerebrospinal venous insufficiency" or "CCSVI" hypothesis, namely that multiple sclerosis (MS) is caused by abnormalities in the azygous and internal jugular veins with subsequent alterations in venous hemodynamics in the central nervous system, has been a dominant topic in MS care in Canada over the past year. Although there is no methodologically rigorous evidence to support this hypothesis presently, a considerable number of MS patients have undergone endovascular CCSVI procedures. Such procedures include angioplasty or stent placement in jugular and azygous veins. The safety and efficacy of these procedures is unknown, but not without risk. Methods: Chart and patient review of five patients with confirmed MS followed in Calgary were undertaken after patients came to medical attention by referral or admission secondary to complications believed to be associated with CCSVI procedures. Results: Complications upon investigation and review included internal jugular vein stent thrombosis, cerebral sinovenous thrombosis, stent migration, cranial nerve injury and injury associated with venous catheterization. Conclusions: As the debate about CCSVI and its relationship to MS continues, the complications and risks associated with venous stenting and angioplasty in jugular and azygous veins are becoming clearer. As increasing numbers of MS patients are seeking such procedures, these five cases represent the beginning of a wave of complications for which standardized care guidelines do not exist. Our experience and that of our colleagues will be used to develop guidelines and strategies to monitor and manage these patients as their numbers increase.